(Q31050729)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

title

Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Fátima Cardoso

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

author name string

Mano MS

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Awada A

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Durbecq V

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Paesmans M

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Larsimont D

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

Piccart M

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

language of work or name

English

0 references

publication date

1 March 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

volume

92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

page(s)

887-895

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

cites work

Cancer statistics, 1994.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Culprit and victim -- DNA topoisomerase II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Molecular analysis of the topoisomerase II alpha gene and its expression in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

DNA topoisomerase IIalpha and -beta expression in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Comparison of Topoisomerase-IIα Gene Status between Primary Breast Cancer and Corresponding Distant Metastatic Sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.010

10.1016/J.YGYNO.2003.12.010

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14984957%20AND%20SRC:MED&resulttype=core&format=json

24 November 2019

1 reference